Credit Suisse’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-10
Closed 4401
2022
Q2
$0 Buy
+10
New +$26 ﹤0.01% 4456

Other funds holding CYT

Credit Suisse's CYT Position: Q3 2022 in Review

Credit Suisse sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 10 shares.

Credit Suisse first reported a position in CYT in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • Credit Suisse reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 10 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Credit Suisse first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Cyteir Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.